A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Alicja PuszkielBenoit YouLéa PayenJonathan LopezJérôme GuittonPascal RoussetJuliette FontaineJulien PéronDenis MailletSophie TartasNathalie BonninVeronique Trillet-LenoirOlivier ColombanDiane Augu-DenechereGilles FreyerMichel TodPublished in: Cancer chemotherapy and pharmacology (2023)
ClinicalTrials.gov Identifier: NCT01932177.